NEWS AND MEDIA
Recent News
Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Development of Over-the-Counter Opioid Overdose Reversal Medication
Lower cost, more accessible medication will help save lives Purdue Pharma L.P. and Harm Reduction Therapeutics, Inc. (HRT) announced today that Purdue will provide up to $6.5 million of additional financial support to HRT to advance its development of a low-cost,…
Speaking Out Against Systemic Racism
WE FEEL compelled at this moment to speak out about the unacceptable and disturbing acts of racial injustice that have brought our nation to an inflection point. WE BELIEVE that any form of racism or racial suppression is wrong. We believe that addressing injustice…
Our Commitment to Safety as we Navigate Coronavirus
We have always been guided by our core values—Collaboration, Integrity, Courage, and Innovation—but now, facing the challenges posed by COVID-19, our core values have taken on new meaning. The health and safety of our colleagues, customers and community, along with…
Purdue Taps Tom Vilsack, former Cabinet Secretary and Governor, to Monitor Compliance With Voluntary Injunction
Purdue Pharma L.P. (“Purdue”) today announced the appointment of former United States Agriculture Secretary and Iowa Governor Tom Vilsack as Monitor under the voluntary self-injunction approved on November 6, 2019, in its chapter 11 bankruptcy case. In its initial…
Purdue Pharma Announces Agreement in Principle on Landmark Opioid Litigation Settlement
Purdue’s entire value to be contributed for the benefit of the American public Settlement is estimated to provide more than $10 billion of value to address opioid crisis, including potentially contributing millions of doses of life-saving opioid overdose reversal…
The Prescription Drug Safety Network Significantly Expands Its Reach in Year 2 and Reports an Average 48% Knowledge Gain Nationwide
Purdue announces expanded support for the Prescription Drug Safety course through an additional sponsorship in Tennessee STAMFORD, Conn. – August 20, 2019 — Purdue Pharma L.P. (“Purdue”), a founding member of the Prescription Drug Safety Network (“the Network”),…
Purdue Pharma L.P. and the National Center for Wellness & Recovery at Oklahoma State University Announce Collaboration Around Research to Address the Opioid Addiction Crisis
Company to provide access to data and intellectual property STAMFORD, Conn./TULSA, Okla., August 15, 2019 – Purdue Pharma L.P. (“Purdue”) and the National Center for Wellness & Recovery (the “Center”) at Oklahoma State University today announced an…
Julie Ducharme, BPharm, MSc, PhD Named Vice President and Chief Scientific Officer of Purdue Pharma L.P.
STAMFORD, CT, July 2, 2019 — Purdue Pharma L.P. today announced that Julie Ducharme, BPharm, MSc, PhD will be joining the organization as Vice President and Chief Scientific Officer with accountability to help progress its existing pipeline and identify new research…
Purdue Pharma Presents Considerations in Opioid Comparator Selection at the College on Problems of Drug Dependence Annual Scientific Meeting
STAMFORD, Conn., June 18, 2019 – Purdue Pharma L.P. presented a poster describing an approach to the evaluation of opioid comparators when assessing the effectiveness of abuse-deterrent formulations (ADFs) of extended-release opioids at the College on Problems of Drug…
Purdue Pharma Announces First Participant Enrolled in Clinical Study Assessing Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose
NAL1002 study will examine pharmacokinetics, safety and tolerability of nalmefene HCl Company will not profit from nalmefene HCl injection Stamford, Conn. – June 6, 2019 – Purdue Pharma L.P. today announced the initiation and first participant enrollment in a Phase 1…